Pay in 4 interest-free payments of $5.15 Learn more
Ships within 48 hours · Estimated delivery Aug 19 - Aug 24
Survodutide's glucagon/GLP-1 dual agonism offers a mechanistically distinct value proposition
To view or add a comment, sign in FDA grants traditional approval to Novartis' Fabhalta (Iptacopan), an an oral Factor B inhibitor to slow the decline of kidney function in adults with primary immunoglobulin A nephropathy (IgAN) recognised as one of the most common autoimmune kidney diseases, with roughly 25 newly diagnosed cases per million people annually worldwide This first-in-class complement inhibitor received the approval through a priority review process after its initial accelerated approval in August 2024 for reducing proteinuria in primary IgAN To view or add a comment, sign in One in five people in the UK have fatty liver disease
What this means for you: Personalized care empowers you to take control of your wellness path with treatments designed around your needs, not a generic protocol
C
T.FujitaM
Identical mRNA for preproglucagon in pancreas and gut
US$ 24.99
US$ 20.91
US$ 25.68
US$ 21.39
US$ 26.16
US$ 20.40
US$ 21.88
US$ 25.74
